HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism.

Abstract
Cannabidiol decreases cerebral infarction and high-mobility group box1 (HMGB1) in plasma in ischemic early phase. However, plasma HMGB1 levels in ischemic delayed phase reach higher concentration with the progressing brain injury. In this study, we investigated the therapeutic time window of cannabidiol on functional deficits, glial HMGB1 and plasma HMGB1 levels in a 4 h mouse middle cerebral artery (MCA) occlusion model. Cannabidiol-treated mice were divided into 3 groups as follows: group (a) treated from day 1, group (b) treated from day 3, group (c) treated from day 5 after MCA occlusion. Moreover, minocycline, microglia inhibitor, and fluorocitrate, an inhibitor of astroglial metabolism, were used to compare with cannabidiol-treated group. Repeated treatment with cannabidiol from 1 and 3 d at the latest after cerebral ischemia improved functional deficits and survival rates. However, cannabidiol from 5 d could not improve the ischemic damage as well as fluorocitrate-treated group. Moreover, both group (a), group (b) and minocycline but not group (c) and fluorocitrate-treated group had a decrease in the number of Iba1 expressing HMGB1 positive cells and HMGB1 levels in plasma. Cannabidiol may provide therapeutic possibilities for the progressing brain injury via HMGB1-inhibiting mechanism.
AuthorsKazuhide Hayakawa, Keiichi Irie, Kazunori Sano, Takuya Watanabe, Sei Higuchi, Makiko Enoki, Takafumi Nakano, Kazuhiko Harada, Shin Ishikane, Tomoaki Ikeda, Masayuki Fujioka, Kensuke Orito, Katsunori Iwasaki, Kenichi Mishima, Michihiro Fujiwara
JournalBiological & pharmaceutical bulletin (Biol Pharm Bull) Vol. 32 Issue 9 Pg. 1538-44 (Sep 2009) ISSN: 1347-5215 [Electronic] Japan
PMID19721229 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • HMGB1 Protein
  • Cannabidiol
Topics
  • Animals
  • Biomarkers (blood)
  • Brain Ischemia (blood, drug therapy, pathology)
  • Cannabidiol (therapeutic use)
  • HMGB1 Protein (blood)
  • Male
  • Mice
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: